Urolithin A in Health and Diseases: Prospects for Parkinson’s Disease Management
Parkinson’s disease (PD) is a chronic and progressive neurodegenerative disorder characterized by a complex pathophysiology and a range of symptoms. The prevalence increases with age, putting the ageing population at risk. Disease management includes the improvement of symptoms, the comfort of the p...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-07-01
|
| Series: | Antioxidants |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-3921/12/7/1479 |
| _version_ | 1797590444968771584 |
|---|---|
| author | Olga Wojciechowska Małgorzata Kujawska |
| author_facet | Olga Wojciechowska Małgorzata Kujawska |
| author_sort | Olga Wojciechowska |
| collection | DOAJ |
| description | Parkinson’s disease (PD) is a chronic and progressive neurodegenerative disorder characterized by a complex pathophysiology and a range of symptoms. The prevalence increases with age, putting the ageing population at risk. Disease management includes the improvement of symptoms, the comfort of the patient’s life, and palliative care. As there is currently no cure, growing evidence points towards the beneficial role of polyphenols on neurodegeneration. Numerous studies indicate the health benefits of the family of urolithins, especially urolithin A (UA). UA is a bacterial metabolite produced by dietary ellagitannins and ellagic acid. An expanding body of literature explores the involvement of the compound in mitochondrial health, and its anti-inflammatory, anti-oxidant, and anti-apoptotic properties. The review organizes the existing knowledge on the role of UA in health and diseases, emphasizing neurodegenerative diseases, especially PD. We gathered data on the potential neuroprotective effect in in vivo and in vitro models. We discussed the possible mechanisms of action of the compound and related health benefits to give a broader perspective of potential applications of UA in neuroprotective strategies. Moreover, we projected the future directions of applying UA in PD management. |
| first_indexed | 2024-03-11T01:21:32Z |
| format | Article |
| id | doaj.art-5edde56b6087499f9887d915ae08adb7 |
| institution | Directory Open Access Journal |
| issn | 2076-3921 |
| language | English |
| last_indexed | 2024-03-11T01:21:32Z |
| publishDate | 2023-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Antioxidants |
| spelling | doaj.art-5edde56b6087499f9887d915ae08adb72023-11-18T18:06:35ZengMDPI AGAntioxidants2076-39212023-07-01127147910.3390/antiox12071479Urolithin A in Health and Diseases: Prospects for Parkinson’s Disease ManagementOlga Wojciechowska0Małgorzata Kujawska1Department of Toxicology, Poznan University of Medical Sciences, Dojazd 30, 60-631 Poznań, PolandDepartment of Toxicology, Poznan University of Medical Sciences, Dojazd 30, 60-631 Poznań, PolandParkinson’s disease (PD) is a chronic and progressive neurodegenerative disorder characterized by a complex pathophysiology and a range of symptoms. The prevalence increases with age, putting the ageing population at risk. Disease management includes the improvement of symptoms, the comfort of the patient’s life, and palliative care. As there is currently no cure, growing evidence points towards the beneficial role of polyphenols on neurodegeneration. Numerous studies indicate the health benefits of the family of urolithins, especially urolithin A (UA). UA is a bacterial metabolite produced by dietary ellagitannins and ellagic acid. An expanding body of literature explores the involvement of the compound in mitochondrial health, and its anti-inflammatory, anti-oxidant, and anti-apoptotic properties. The review organizes the existing knowledge on the role of UA in health and diseases, emphasizing neurodegenerative diseases, especially PD. We gathered data on the potential neuroprotective effect in in vivo and in vitro models. We discussed the possible mechanisms of action of the compound and related health benefits to give a broader perspective of potential applications of UA in neuroprotective strategies. Moreover, we projected the future directions of applying UA in PD management.https://www.mdpi.com/2076-3921/12/7/1479urolithin AellagitanninsParkinson’s diseasegut microbiotaneuroprotectionmitochondria |
| spellingShingle | Olga Wojciechowska Małgorzata Kujawska Urolithin A in Health and Diseases: Prospects for Parkinson’s Disease Management Antioxidants urolithin A ellagitannins Parkinson’s disease gut microbiota neuroprotection mitochondria |
| title | Urolithin A in Health and Diseases: Prospects for Parkinson’s Disease Management |
| title_full | Urolithin A in Health and Diseases: Prospects for Parkinson’s Disease Management |
| title_fullStr | Urolithin A in Health and Diseases: Prospects for Parkinson’s Disease Management |
| title_full_unstemmed | Urolithin A in Health and Diseases: Prospects for Parkinson’s Disease Management |
| title_short | Urolithin A in Health and Diseases: Prospects for Parkinson’s Disease Management |
| title_sort | urolithin a in health and diseases prospects for parkinson s disease management |
| topic | urolithin A ellagitannins Parkinson’s disease gut microbiota neuroprotection mitochondria |
| url | https://www.mdpi.com/2076-3921/12/7/1479 |
| work_keys_str_mv | AT olgawojciechowska urolithinainhealthanddiseasesprospectsforparkinsonsdiseasemanagement AT małgorzatakujawska urolithinainhealthanddiseasesprospectsforparkinsonsdiseasemanagement |